Company Profile
Tonix Pharmaceuticals Stock Price, News & Analysis
- Ticker:
- TNXP
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
11.65 USD (+3.46%)
Close
Last updated: August 6, 2026
187M USD
Market cap
Why the stock is moving
The latest company update was “Tonix Pharmaceuticals to Participate in Upcoming Investor Conferences”. TNXP changed 0.45% and closed at $11.26 on Aug 5, 2026, indicating a relatively limited closing-price reaction to this commercial update.
Company overview
Commercial Fibromyalgia Franchise
Tonix Pharmaceuticals is a commercial-stage biopharmaceutical company centered on TONMYA, a bedtime treatment for fibromyalgia. The product is intended to address nonrestorative sleep and other core features of the disease and represents the company's principal commercial franchise.
Infectious-Disease Pipeline
Beyond its commercial business, Tonix is developing TNX-4800, a long-acting human monoclonal antibody designed to prevent Lyme disease by targeting outer surface protein A on *Borrelia burgdorferi*.
Broader Development Platform
The company also maintains mid-stage and earlier-stage programs spanning immunology, infectious diseases and central nervous system disorders, giving it a mixed commercial-and-development-stage operating profile.
Future catalysts
Initiation of an adaptive Phase 2 U.S. field study of TNX-4800 in the first half of 2027, pending FDA agreement.
Recent news
- 01
Tonix Pharmaceuticals to Participate in Upcoming Investor Conferences
Source: Tonix Pharmaceuticals
- 02
- 03
Tonix Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 10, 2026
Source: Tonix Pharmaceuticals
- 04
- 05
Tonix Pharmaceuticals Announces Major Managed Medicare Payer Agreement for TONMYA®
Source: Tonix Pharmaceuticals
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Tonix Pharmaceuticals (TNXP)?
Tonix Pharmaceuticals (TNXP) most recently closed at 11.65 USD, a +3.46% move versus the previous session.
What is the market cap of Tonix Pharmaceuticals (TNXP)?
Tonix Pharmaceuticals currently has a market capitalization of 187M USD on BioPharmSignal.
What does Tonix Pharmaceuticals do?
Commercial Fibromyalgia Franchise Tonix Pharmaceuticals is a commercial-stage biopharmaceutical company centered on TONMYA, a bedtime treatment for fibromyalgia. The product is intended to address nonrestorative sleep and other core features of the disease and represents the company's principal commercial franchise. Infectious-Disease Pipeline Beyond its...
On which exchange is TNXP stock listed?
Tonix Pharmaceuticals (TNXP) is associated with NASDAQ, United States, Biopharma.
What is TNX-4800?
field study of TNX-4800 in the first half of 2027, pending FDA agreement.
Which conditions is Tonix Pharmaceuticals targeting with TNX-4800?
Tonix Pharmaceuticals is associated with immunology based on its company overview and current catalyst commentary.
How does Tonix Pharmaceuticals describe recent progress with TNX-4800?
field study of TNX-4800 in the first half of 2027, pending FDA agreement.
What is Commercial?
Commercial Fibromyalgia Franchise Tonix Pharmaceuticals is a commercial-stage biopharmaceutical company centered on TONMYA, a bedtime treatment for fibromyalgia.